Condition (MeSH)
Ophthalmoplegia, Chronic Progressive External
ClinicalTrials.gov lists 14 trials for Ophthalmoplegia, Chronic Progressive External or a narrower condition beneath it. Amgen has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 14 trials are tagged with Ophthalmoplegia, Chronic Progressive External itself; the rest are tagged with a narrower condition beneath it.
When did Ophthalmoplegia, Chronic Progressive External trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2019 | 1 |
| 2017 | 1 |
| 2015 | 1 |
| 2014 | 3 |
| 2011 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 14 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ophthalmoplegia, Chronic Progressive External trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Not applicable | 2 |
| Observational | 7 |
How many Ophthalmoplegia, Chronic Progressive External trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Completed | 9 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ophthalmoplegia, Chronic Progressive External trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Amgen | 2 |
| Abliva AB | 1 |
| Khondrion BV | 1 |
| Stealth BioTherapeutics Inc. | 1 |
| The Emmes Company, LLC | 1 |
Which drugs are being tested for Ophthalmoplegia, Chronic Progressive External? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (Cystagon) Cysteamine Bitartrate | 2 |
| Nicotinamide Riboside | 1 |
| Elamipretide | 1 |
| KH176 | 1 |
| KL1333 | 1 |
Which serious adverse events do Ophthalmoplegia, Chronic Progressive External trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Vomiting | 5 | 2 |
| Convulsion | 4 | 2 |
| Dehydration | 3 | 2 |
| Status epilepticus | 2 | 2 |
| Acute respiratory failure | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Ophthalmoplegia, Chronic Progressive External? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. | Journal of medical genetics | 2020 | Yes |
| MtDNA-maintenance defects: syndromes and genes. | Journal of inherited metabolic disease | 2017 | Yes |
| The genetic basis of incomitant strabismus: consolidation of the current knowledge of the genetic foundations of disease. | Seminars in ophthalmology | 2013 | Yes |
| Ocular motility findings in chronic progressive external ophthalmoplegia. | Eye (London, England) | 2005 | Yes |
| Defects in mitochondrial DNA replication and human disease. | Critical reviews in biochemistry and molecular biology | 2012 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.